Table 3.
Characteristics of hypertensive patients at baseline (T0) and after 6-month antihypertensive therapy (T1) according to the treatment assigned.
| Enalapril (T0) |
Enalapril (T1) |
Δ% p (MWW) |
Losartan (T0) |
Losartan (T1) |
Δ% p (MWW) |
Olmesartan (T0) |
Olmesartan (T1) |
Δ% p (MWW) |
KW * | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number | 27 | 29 | 26 | |||||||
| Gender (m/f) | 20/7 | 21/8 | 20/6 | |||||||
| BMI (kg/m2) | 24.4 (1.2) | 24 (2) | −3.11 p < 0.001 | 25 (6) | 25 (4) | −2.83 p = 0.001 |
25.3 (3.4) | 25 (2.27) | −3.78 p < 0.001 |
p = 0.740 |
| SBP (mmHg) | 155 (10) | 120 (10) | −18.9 p < 0.001 |
160 (15) | 130 (18) | −17.2 p < 0.001 |
150 (11) | 120 (5) | −19.3 p < 0.001 |
p = 0.089 |
| DBP (mmHg) | 80 (5) | 70 (0) | −16.3 p < 0.001 |
85 (10) | 70 (10) | −14.3 p < 0.001 |
80 (10) | 60 (10) | −24 p < 0.001 |
p < 0.001 |
| TC (mg/dL) | 169 (22) | 170 (30) | −2.36 p = 0.007 |
180 (40) | 180 (35) | −2.63 p < 0.001 |
165 (44) | 160 (33) | −2.3 p = 0.01 |
p = 0.974 |
| HDL-C (mg/dL) | 46 (6) | 48 (4) | 3.9 p < 0.001 |
45 (9) | 47 (5) | 2.14 p = 0.009 |
48 (2) | 49 (1) | 3.32 p = 0.02 |
p = 0.316 |
| TG (mg/dL) | 120 (31) | 120 (19) | 4.1 p = 0.273 |
120 (18) | 113 (10) | 0.51 p = 0.927 |
120 (37) | 120 (29) | 0.66 p = 0.821 |
p = 0.352 |
| LDL-C (mg/dL) | 101 (29.4) | 93 (33.8) | −6.6 p < 0.001 |
113 (40.3) | 108 (32) | −4.7 p < 0.001 |
93.1(41.3) | 84 (31.5) | −4.9 p = 0.007 |
p = 0.542 |
| Glucose (mg/dL) | 85 (11) | 90 (10) | 0.31 p = 0.876 |
86 (12) | 80 (10) | −3.6 p = 0.002 |
89 (11) | 88 (10) | −3.1 p = 0.008 |
p = 0.008 |
| HsCRP (mg/dL) | 0.82 (0.11) | 0.69 (0.18) | −18.4 p < 0.001 |
0.82 (0.12) | 0.73 (0.15) | −13.1 p < 0.001 |
0.7 (0.23) | 0.54 (0.21) | −21.4 p < 0.001 |
p = 0.002 |
| Fibrinogen (mg/dL) | 302.8 (41.2) | 295 (62) | −9.39 p < 0.001 |
324 (33.4) | 290 (37) | −10.63 p < 0.001 |
287.2 (72.3) | 242.4 (45) | −13.1 p < 0.001 |
p = 0.018 |
| AIx (%) | 12.8 (5.3) | 7 (3.3) | −45.9 p < 0.001 |
16.2 (9.2) | 7 (7.8) | −44.8 p < 0.001 |
11.1 (7.1) | 4 (4.8) | −56.8 p < 0.001 |
p = 0.007 |
| PWV (m/s) | 8 (2.3) | 5.6 (2.2) | −29.7 p < 0.001 |
8.6 (1.6) | 5.4 (2.1) | −33.2 p < 0.001 |
7.4 (2.1) | 4.4 (1.0) | −33.5 p < 0.001 |
p = 0.491 |
| miR-221 (n-fold) | 1.87 (0.74) | 1.35 (0.06) | −28.1 p < 0.001 |
2.05 (0.32) | 1.5 (0.17) | −24 p < 0.001 |
1.64 (0.7) | 1.11 (0.76) | −33.6 p < 0.001 |
p = 0.055 |
| miR-222 (n-fold) | 1.89 (0.08) | 1.27 (0.29) | −36.1 p < 0.001 |
2.06 (0.42) | 1.33 (0.35) | −34.3 p < 0.001 |
1.8 (0.19) | 1.18 (0.05) | −37.9 p < 0.001 |
p < 0.634 |
| miR-145 (n-fold) | 0.62 (0.15) | 0.98 (0.15) | 49.7 p < 0.001 |
0.57(0.1) | 0.75 (0.17) | 31.5 p < 0.001 |
0.68(0.22) | 0.95 (0.11) | 44.7 p < 0.001 |
p = 0.001 |
Data are presented as median (IQR). MWW, Mann–Whitney/Wilcoxon test; p, significance level to statistic test to MWW (T1 vs. T0) KW, Kruskal–Wallis test; p, significance level to statistic test to KW. * significant p-values were tested by two-by-two comparisons with Bonferroni correction; for details see Table 4.